
|Articles|December 1, 2002
Anecortave acetate administration shows promise for subfoveal, exudative AMD
San Francisco-The angiostatic steroid anecortave acetate continues to show promise as a safe and effective treatment for subfoveal, exudative age-related macular degeneration (AMD), according to results from an interim analysis of an ongoing phase II trial.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Pickleball, fireworks, eyecare in space, and IRIS registry data among lead stories from day 1 of AAO 2025
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
AAO 2025: The outcomes of the VERONA and DAVIO-2 studies set up continued phase 3 research
4
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
5